BAKER BROS. ADVISORS LP Q1 2021 Filing
Filed May 17, 2021
Portfolio Value
$23.1B
Holdings
126
Report Date
Q1 2021
Filing Type
13F-HR
All Holdings (126 positions)
| Stock | Value |
|---|---|
SGENUSDSeagen Inc. | $6.6T |
ONCBeiGene, Ltd. | $4.1T |
INCYIncyte Corporation | $2.6T |
KODKodiak Sciences Inc. | $1.6T |
ACADACADIA Pharmaceuticals Inc. | $1.1T |
ALXNAlexion Pharmaceuticals, Inc. | $610.6B |
NVTA1EURInvitae Corporation | $601.8B |
BMRNBioMarin Pharmaceutical Inc. | $573.1B |
ASNDAscendis Pharma A/S | $456.3B |
PRLDPrelude Therapeutics Incorporated | $438.7B |
ABCLAbCellera Biologics Inc. | $354.9B |
ARGXargenx SE | $308.3B |
1K0IGM Biosciences, Inc. | $242.0B |
MRTXEURMirati Therapeutics, Inc. | $241.5B |
MDGLMadrigal Pharmaceuticals, Inc. | $175.4B |
AMRNAmarin Corporation plc | $164.3B |
GBTUSDGlobal Blood Therapeutics, Inc. | $131.1B |
BCRXBioCryst Pharmaceuticals, Inc. | $129.3B |
IMCRImmunocore Holdings plc | $107.3B |
PACBPacific Biosciences of California, Inc. | $106.7B |
TILInstil Bio, Inc. | $97.7B |
—Talis Biomedical Corporation | $97.3B |
HRTXHeron Therapeutics, Inc. | $97.2B |
CERSCerus Corporation | $82.4B |
ALLKGUSDAllakos Inc. | $80.7B |
—DBV Technologies S.A. | $77.9B |
NRIXNurix Therapeutics, Inc. | $76.3B |
KYMRKymera Therapeutics, Inc. | $76.1B |
RYTMRhythm Pharmaceuticals, Inc. | $74.0B |
IM8NInsmed Incorporated | $73.4B |
APLSApellis Pharmaceuticals, Inc. | $71.8B |
NBIXNeurocrine Biosciences, Inc. | $65.8B |
KRYSKrystal Biotech, Inc. | $58.6B |
—Forma Therapeutics Holdings, Inc. | $56.7B |
HZNPHorizon Therapeutics Public Ltd Co | $55.1B |
BCELAtreca, Inc. | $54.2B |
—Zymeworks Inc. | $54.0B |
ADAPYAdaptimmune Therapeutics plc | $52.2B |
KNSAKiniksa Pharmaceuticals, Ltd. | $51.8B |
RAREUltragenyx Pharmaceutical Inc. | $50.6B |
—Neoleukin Therapeutics, Inc. | $47.0B |
IMTXImmatics N.V. | $44.8B |
DSGNDesign Therapeutics, Inc. | $43.0B |
698Achilles Therapeutics plc | $42.9B |
MRUSMerus N.V. | $42.6B |
VSTMVerastem, Inc. | $42.0B |
BCABBioAtla, Inc. | $41.9B |
ALTAltimmune, Inc. | $39.0B |
FLGTFulgent Genetics, Inc. | $38.7B |
PTGXProtagonist Therapeutics, Inc. | $37.2B |
ALGSAligos Therapeutics, Inc. | $36.6B |
AXSMAxsome Therapeutics, Inc. | $35.6B |
ADCTADC Therapeutics SA | $34.6B |
CCXIEURChemoCentryx, Inc. | $33.6B |
OPTEYOpthea Limited | $31.7B |
AGLEUSDAeglea BioTherapeutics, Inc. | $27.0B |
NVV1Novavax, Inc. | $26.1B |
ALKSAlkermes plc | $22.9B |
MREOMereo BioPharma Group plc | $22.6B |
RETAEURReata Pharmaceuticals, Inc. | $22.3B |
OTICEUROtonomy, Inc. | $18.4B |
AUPHAurinia Pharmaceuticals Inc. | $18.3B |
EWTXEdgewise Therapeutics, Inc. | $16.3B |
XNCRXencor, Inc. | $15.9B |
—Invitae Corporation | $15.6B |
BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | $15.3B |
—Athira Pharma, Inc. | $14.8B |
BDQMAlbireo Pharma, Inc. | $14.5B |
XENEXenon Pharmaceuticals Inc. | $13.5B |
MIRMMirum Pharmaceuticals, Inc. | $12.8B |
SRPT 1.5 11/15/24Sarepta Therapeutics, Inc. | $12.0B |
290AChinook Therapeutics, Inc. | $11.6B |
SPRYSilverback Therapeutics, Inc. | $10.4B |
RVMDRevolution Medicines, Inc. | $10.2B |
CBAYUSDCymabay Therapeutics, Inc. | $9.9B |
—Genetron Holdings Limited | $9.8B |
HOOKGBPHOOKIPA Pharma Inc. | $9.4B |
CRNXCrinetics Pharmaceuticals, Inc. | $9.4B |
ANABAnaptysBio, Inc. | $9.2B |
OPHTEURIVERIC bio, Inc. | $8.7B |
NGMUSDNGM Biopharmaceuticals, Inc. | $8.5B |
KRTXKaruna Therapeutics, Inc. | $8.4B |
—Gamida Cell Ltd. | $8.4B |
ASMBAssembly Biosciences, Inc. | $7.1B |
CABACabaletta Bio, Inc. | $7.1B |
—bluebird bio, Inc. | $6.8B |
MGNXMacroGenics, Inc. | $6.4B |
BNRBurning Rock Biotech Limited | $5.6B |
—NexImmune, Inc. | $5.6B |
GBYSangamo Therapeutics, Inc. | $5.4B |
ORTXUSDOrchard Therapeutics plc | $5.3B |
—Syros Pharmaceuticals, Inc. | $5.2B |
5E7Iteos Therapeutics, Inc. | $5.1B |
DNLIDenali Therapeutics Inc. | $5.1B |
ALECAlector, Inc. | $4.8B |
—Evofem Biosciences, Inc. | $4.7B |
REPLReplimune Group, Inc. | $4.7B |
TVTXTravere Therapeutics, Inc. | $4.7B |
SRPTSarepta Therapeutics, Inc. | $4.4B |
PASGPassage Bio, Inc. | $4.1B |
Page 1 of 2Next